DALLAS, TX--(Marketwired - May 7, 2013) - Cerebain Biotech Corp. ("Cerebain" or "the Company"), a subsidiary of Discount Dental Materials, Inc. (OTCBB: [ DDOO ]) announced today that its company information is available via Standard & Poor's Corporation Records Listing Program. As part of the program, a full description of Discount Dental Materials, Inc. will be published in the Daily News Section of Standard & Poor's Corporation Records, a recognized securities manual for secondary trading in up to 38 States under the Blue Sky Laws. Standard & Poor's Corporation Records is available in print, CD-ROM, and via the web at [ www.netadvantage.standardandpoors.com ] as well as through numerous electronic vendors.

The company information about Discount Dental Materials, Inc. to be made available through this program includes an in-depth description of the Discount Dental Materials, Inc.'s business operations, share price, dividend history, shares outstanding, company financial position, earnings, and full income statement and balance sheet.

About Discount Dental Materials, Inc.

Discount Dental Materials, Inc. was incorporated in Nevada on December 17, 2007. The Company's business involves the discovery of products for the treatment of Alzheimer's disease utilizing Omentum. The Company's planned products include both a medical device solution as well as a synthetic drug solution. The Company's operations are conducted through its wholly-owned subsidiary, Cerebain Biotech Corp. For more information about Discount Dental and Cerebain Biotech, please visit the Company's website at [ www.cerebain.com ] and [ www.otcmarkets.com ], under the ticker symbol "DDOO," to view the Company's public filings and stock quote.

About S&P Capital IQ

S&P Capital IQ, a business line of The McGraw-Hill Companies (NYSE: [ MHP ]), is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. We provide a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations, and Compustat; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit [ www.spcapitaliq.com ].

Company information distributed through the Corporation Records Program is based upon information that S&P Capital IQ considers to be reliable, but neither S&P Capital IQ nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.

Forward Looking Statements

This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.